Across TCGA pan-cancer cohorts, LRIT2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated LRIT2 data layer compared with 6 for mutation status.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LRIT2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LRIT2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LGG show a favorable association.
BRCA, LGG, and OV are the cancer types where LRIT2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.